The trends and hotspots of immunotherapy for metastatic colorectal cancer from 2013 to 2022: A bibliometric and visual analysis

References

• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–13. doi:10.3322/caac.21660. Cited in: Pubmed; PMID 33538338.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Stadler ZK, Cercek A, Mendelsohn RB, Shia J, Segal NH, Diaz LA. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019 Jun;16(6):361–75. doi:10.1038/s41575-019-0126-x. Cited in: Pubmed; PMID 30886395.
   PubMed Web of Science ®Google Scholar
• Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021 Feb 16;325(7):669–685. doi:10.1001/jama.2021.0106. Cited in: Pubmed; PMID 33591350.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020 Aug;17(8):807–821. doi:10.1038/s41423-020-0488-6. Cited in: Pubmed; PMID 32612154.
   PubMed Web of Science ®Google Scholar
• Andre T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al. Pembrolizumab in microsatellite-instability–high advanced colorectal cancer. N Engl J Med. 2020 Dec 3;383(23):2207–18. doi:10.1056/NEJMoa2017699. Cited in: Pubmed; PMID 33264544.
   PubMed Web of Science ®Google Scholar
• Andre T, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Ann Oncol. 2022 Oct;33(10):1052–60. doi:10.1016/j.annonc.2022.06.008. Cited in: Pubmed; PMID 35764271.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer. J Clin Oncol. 2018 Mar 10;36(8):773–9. doi:10.1200/JCO.2017.76.9901. Cited in: Pubmed; PMID 29355075.
   PubMed Web of Science ®Google Scholar
• Wang S, Wu K, Zhang Z, Xu Z, Wu J, Xu S. Mapping theme trends and recognizing research hot spots in the use of ultrasound in orthopaedics: a bibliometric analysis of global research. Am J Transl Res. 2021;13:9892.
   PubMed Web of Science ®Google Scholar
• Aggarwal A, Lewison G, Idir S, Peters M, Aldige C, Boerckel W, Boyle P, Trimble EL, Roe P, Sethi T, et al. The state of lung cancer research: a global analysis. J Thorac Oncol. 2016 Jul;11(7):1040–50. doi:10.1016/j.jtho.2016.03.010. Cited in: Pubmed; PMID 27013405.
   PubMed Web of Science ®Google Scholar
• Moral-Muñoz JA, Herrera-Viedma E, Santisteban-Espejo A, Cobo MJ. Software tools for conducting bibliometric analysis in science: an up-to-date review. Profesional de la Información. 2020;29(1). doi:10.3145/epi.2020.ene.03.
   Web of Science ®Google Scholar
• Chen C. CiteSpace II: detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol. 2006;57(3):359–77. doi:10.1002/asi.20317.
   Web of Science ®Google Scholar
• Van Eck N, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3.
   PubMed Web of Science ®Google Scholar
• Zhang J, Song L, Xu L, Fan Y, Wang T, Tian W, Ju J, Xu H. Knowledge domain and emerging trends in ferroptosis research: a bibliometric and knowledge-map analysis. Front Oncol. 2021;11:686726. doi:10.3389/fonc.2021.686726. Cited in: Pubmed; PMID 34150654.
   PubMed Web of Science ®Google Scholar
• Lotka AJ. The frequency distribution of scientific productivity. J Wash Acad Sci. 1926;16:317–23.
   Google Scholar
• Liu G, Jiang R, Jin Y. Sciatic nerve injury repair: a visualized analysis of research fronts and development trends. Neural Regen Res. 2014;9(18):1716. doi:10.4103/1673-5374.141810.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350–6. doi:10.1038/nm.3967. Cited in: Pubmed; PMID 26457759.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252–64. doi:10.1038/nrc3239. Cited in: Pubmed; PMID 22437870.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012 Jun 28;366(26):2443–54. doi:10.1056/NEJMoa1200690. Cited in: Pubmed; PMID 22658127.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015 Jan;5(1):43–51. doi:10.1158/2159-8290.CD-14-0863. Cited in: Pubmed; PMID 25358689.
   PubMed Web of Science ®Google Scholar
• Fan A, Wang B, Wang X, Nie Y, Fan D, Zhao X, Lu Y. Immunotherapy in colorectal cancer: current achievements and future perspective. Int J Biol Sci. 2021;17(14):3837–49. doi:10.7150/ijbs.64077. Cited in: Pubmed; PMID 34671202.
   PubMed Web of Science ®Google Scholar
• Xiao F, Li C, Sun J, Zhang L. Knowledge domain and emerging trends in organic photovoltaic technology: a scientometric review based on citespace analysis. Front Chem. 2017;5:67. doi:10.3389/fchem.2017.00067.
   PubMed Web of Science ®Google Scholar
• Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019 Jun 13;38(1):255. doi:10.1186/s13046-019-1259-z. Cited in: Pubmed; PMID 31196207.
   PubMedGoogle Scholar
• Lee MS, Loehrer PJ, Imanirad I, Cohen S, Ciombor KK, Moore DT, Carlson CA, Sanoff HK, McRee AJ. Phase II study of ipilimumab, nivolumab, and panitumumab in patients with KRAS/NRAS/BRAF wild-type (WT) microsatellite stable (MSS) metastatic colorectal cancer (mCRC). Am Soc Clin Oncol. 2021;39(3_suppl):7–7. doi:10.1200/JCO.2021.39.3_suppl.7.
   Google Scholar
• Bendell JC, Powderly JD, Lieu CH, Eckhardt SG, Hurwitz H, Hochster HS, Murphy JE, Funke RP, Rossi C, Wallin J, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). Am J Clin Oncol. 2015;33(3_suppl):704–704. doi:10.1200/jco.2015.33.3_suppl.704.
   Google Scholar
• McLaughlin M, Patin EC, Pedersen M, Wilkins A, Dillon MT, Melcher AA, Harrington KJ. Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer. 2020 Apr;20(4):203–17. doi:10.1038/s41568-020-0246-1. Cited in: Pubmed; PMID 32161398.
   PubMed Web of Science ®Google Scholar
• Parikh AR, Clark JW, Wo JY, Yeap BY, Allen JN, Blaszkowsky LS, Ryan DP, Giantonio BJ, Weekes CD, Zhu AX, et al. A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC). Am Soc Clin Oncol. 2019;37(15_suppl):3514–3514. doi:10.1200/JCO.2021.37.15_suppl.3514.
   Google Scholar
• Ebert PJR, Cheung J, Yang Y, McNamara E, Hong R, Moskalenko M, Gould SE, Maecker H, Irving BA, Kim JM, et al. MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade. Immunity. 2016 Mar 15;44(3):609–621. doi:10.1016/j.immuni.2016.01.024. Cited in: Pubmed; PMID 26944201.
   PubMed Web of Science ®Google Scholar
• AG FH-LR. A study of the safety, pharmacokinetics, and therapeutic activity of RO6958688 in combination with atezolizumab in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors. clinicaltrials gov/ct2/show/NCT02650713.
   Google Scholar
• Yarchoan M, Huang CY, Zhu Q, Ferguson AK, Durham JN, Anders RA, Thompson ED, Rozich NS, Thomas DL, Nauroth JM, et al. A phase 2 study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair proficient advanced colorectal cancer. Cancer Med. 2020 Feb;9(4):1485–94. doi:10.1002/cam4.2763. Cited in: Pubmed; PMID 31876399.
   PubMed Web of Science ®Google Scholar
• Harb WA, Cerec V, McElwaine-Johnn H, Champion B, Alvis S, Jain N, Ellis C, Fisher K, Beadle JW. A phase I study of pembrolizumab in combination with enadenotucirev (EnAd)(spice) in subjects with metastatic or advanced carcinoma. Am J Clin Oncol. 2016;34(15_suppl):3112–3112. doi:10.1200/JCO.2016.34.15_suppl.TPS3112.
   Google Scholar
• Mager LF, Burkhard R, Pett N, Cooke NCA, Brown K, Ramay H, Paik S, Stagg J, Groves RA, Gallo M, et al. Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy. Science. 2020 Sep 18;369(6510):1481–1489. doi:10.1126/science.abc3421. Cited in: Pubmed; PMID 32792462.
   PubMed Web of Science ®Google Scholar
• Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017 Nov 6;27(21):1147–51. 10.1016/j.cub.2017.09.019. Cited in: Pubmed; PMID 29112863.
   Web of Science ®Google Scholar
• Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020 Oct 2;5(52). doi:10.1126/sciimmunol.aba0759. Cited in: Pubmed; PMID 33008914.
   Web of Science ®Google Scholar
• Tang H, Qiao J, Fu YX. Immunotherapy and tumor microenvironment. Cancer Lett. 2016 Jan 1;370(1):85–90. 10.1016/j.canlet.2015.10.009. Cited in: Pubmed; PMID 26477683.
   PubMed Web of Science ®Google Scholar
• Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019 Sep 9;38(1):396. doi:10.1186/s13046-019-1396-4. Cited in: Pubmed; PMID 31500650.
   PubMed Web of Science ®Google Scholar
• Kraman M, Bambrough PJ, Arnold JN, Roberts EW, Magiera L, Jones JO, Gopinathan A, Tuveson DA, Fearon DT. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein–α. Science. 2010 Nov 5;330(6005):827–30. 10.1126/science.1195300. Cited in: Pubmed; PMID 21051638.
   PubMed Web of Science ®Google Scholar
• Wen Y, Wang CT, Ma TT, Li ZY, Zhou LN, Mu B, Leng F, Shi H-S, Li Y-O, Wei Y-Q, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci. 2010 Nov;101(11):2325–32. doi:10.1111/j.1349-7006.2010.01695.x. Cited in: Pubmed; PMID 20804499.
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, Katsaros D, O’Brien-Jenkins A, Gimotty PA, Coukos G, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med. 2008 Jan;14(1):28–36. doi:10.1038/nm1699. Cited in: Pubmed; PMID 18157142.
   PubMed Web of Science ®Google Scholar
• Quatromoni JG, Eruslanov E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res. 2012;4(4):376–89. Cited in: Pubmed; PMID 23145206.
   PubMed Web of Science ®Google Scholar
• Rodriguez PC, Zea AH, DeSalvo J, Culotta KS, Zabaleta J, Quiceno DG, Ochoa JB, Ochoa AC. L -arginine consumption by macrophages modulates the expression of CD3ζ Chain in T lymphocytes. J Immunol. 2003 Aug 1;171(3):1232–9. 10.4049/jimmunol.171.3.1232. Cited in: Pubmed; PMID 12874210.
   PubMed Web of Science ®Google Scholar
• Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, Benyamin FW, Man Lei Y, Jabri B, Alegre M-L, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy. Science. 2015 Nov 27;350(6264):1084–9. doi:10.1126/science.aac4255. Cited in: Pubmed; PMID 26541606.
   PubMed Web of Science ®Google Scholar
• Vetizou M, Pitt JM, Daillere R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CPM, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015 Nov 27;350(6264):1079–84. doi:10.1126/science.aad1329. Cited in: Pubmed; PMID 26541610.
   PubMed Web of Science ®Google Scholar
• Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019 Jul 15;7(1):183. 10.1186/s40425-019-0647-4. Cited in: Pubmed; PMID 31307554.
   PubMedGoogle Scholar
• Panda A, Betigeri A, Subramanian K, Ross JS, Pavlick DC, Ali S, Markowski P, Silk A, Kaufman HL, Lattime E, et al. Identifying a clinically applicable mutational burden threshold as a potential biomarker of response to immune checkpoint therapy in solid tumors. JCO Precis Oncol. 2017;(1):1–13. doi:10.1200/PO.17.00146. Cited in: Pubmed; PMID 29951597.
   Google Scholar
• Pages F, Mlecnik B, Marliot F, Bindea G, Ou FS, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD, et al. International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018 May 26;391(10135):2128–2139. doi:10.1016/S0140-6736(18)30789-X. Cited in: Pubmed; PMID 29754777.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Leone F, McDermott RS, Morse MA, Wong KYM, Neyns B, Leach JL, Garcia Alfonso P, Lee JJ, et al. Nivolumab in patients with DNA mismatch repair deficient/microsatellite instability high metastatic colorectal cancer: update from CheckMate 142. Am Soc Clin Oncol. 2017;35(4_suppl):519–519. doi:10.1200/JCO.2017.35.4_suppl.519.
   Google Scholar